NTGN—I concur with the viewpoint in your Twitter link, even while recognizing that the tweeter is an executive at a potentially competing company. Not testing monotherapy in phase-1 is curious, to say the least.
A cynic might say that NTGN didn’t examine NEO-PV-1 single-agent activity because they did not expect any, based on preclinical data.
Meanwhile… GRTS is hovering close to its IPO price after the unexplained pop last week.
Market Data 
Markets 
